BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28548080)

  • 1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
    San José-Enériz E; Agirre X; Rabal O; Vilas-Zornoza A; Sanchez-Arias JA; Miranda E; Ugarte A; Roa S; Paiva B; Estella-Hermoso de Mendoza A; Alvarez RM; Casares N; Segura V; Martín-Subero JI; Ogi FX; Soule P; Santiveri CM; Campos-Olivas R; Castellano G; de Barrena MGF; Rodriguez-Madoz JR; García-Barchino MJ; Lasarte JJ; Avila MA; Martinez-Climent JA; Oyarzabal J; Prosper F
    Nat Commun; 2017 May; 8():15424. PubMed ID: 28548080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
    Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; Vilas-Zornoza A; Ugarte A; de Miguel I; Miranda E; Garate L; Fraga M; Santamarina P; Fernandez Perez R; Ordoñez R; Sáez E; Roa S; García-Barchino MJ; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
    J Med Chem; 2018 Aug; 61(15):6518-6545. PubMed ID: 29953809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
    Rabal O; Sánchez-Arias JA; San José-Enériz E; Agirre X; de Miguel I; Garate L; Miranda E; Sáez E; Roa S; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
    J Med Chem; 2018 Aug; 61(15):6546-6573. PubMed ID: 29890830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
    Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; de Miguel I; Ordoñez R; Garate L; Miranda E; Sáez E; Vilas-Zornoza A; Pineda-Lucena A; Estella A; Zhang F; Wu W; Xu M; Prosper F; Oyarzabal J
    J Med Chem; 2021 Mar; 64(6):3392-3426. PubMed ID: 33661013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights for the design of protein lysine methyltransferase G9a inhibitors.
    Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
    Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
    Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
    Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
    Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
    Colyn L; Bárcena-Varela M; Álvarez-Sola G; Latasa MU; Uriarte I; Santamaría E; Herranz JM; Santos-Laso A; Arechederra M; Ruiz de Gauna M; Aspichueta P; Canale M; Casadei-Gardini A; Francesconi M; Carotti S; Morini S; Nelson LJ; Iraburu MJ; Chen C; Sangro B; Marin JJG; Martinez-Chantar ML; Banales JM; Arnes-Benito R; Huch M; Patino JM; Dar AA; Nosrati M; Oyarzábal J; Prósper F; Urman J; Cubero FJ; Trautwein C; Berasain C; Fernandez-Barrena MG; Avila MA
    Hepatology; 2021 Jun; 73(6):2380-2396. PubMed ID: 33222246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
    Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
    Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
    Kondengaden SM; Luo LF; Huang K; Zhu M; Zang L; Bataba E; Wang R; Luo C; Wang B; Li KK; Wang PG
    Eur J Med Chem; 2016 Oct; 122():382-393. PubMed ID: 27393948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
    Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
    J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.
    Agarwal P; Jackson SP
    Cancer Lett; 2016 Oct; 380(2):467-475. PubMed ID: 27431310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.
    Fahy J; Jeltsch A; Arimondo PB
    Expert Opin Ther Pat; 2012 Dec; 22(12):1427-42. PubMed ID: 23033952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic small molecule modulators of histone and DNA methylation.
    Hauser AT; Robaa D; Jung M
    Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G9a - An Appealing Antineoplastic Target.
    Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
    Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells.
    Cao YP; Sun JY; Li MQ; Dong Y; Zhang YH; Yan J; Huang RM; Yan X
    Acta Pharmacol Sin; 2019 Aug; 40(8):1076-1084. PubMed ID: 30765842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.
    Rotili D; Tarantino D; Marrocco B; Gros C; Masson V; Poughon V; Ausseil F; Chang Y; Labella D; Cosconati S; Di Maro S; Novellino E; Schnekenburger M; Grandjenette C; Bouvy C; Diederich M; Cheng X; Arimondo PB; Mai A
    PLoS One; 2014; 9(5):e96941. PubMed ID: 24810902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
    Lenstra DC; Al Temimi AHK; Mecinović J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
    Fandy TE; Carraway H; Gore SD
    Cancer J; 2007; 13(1):40-8. PubMed ID: 17464245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells.
    Zhang J; Yao D; Jiang Y; Huang J; Yang S; Wang J
    Bioorg Chem; 2017 Jun; 72():168-181. PubMed ID: 28460359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.